title: Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity.
abstract: Liposomes loaded with the rhenium compound (bis-dimethylsulfoxido-cis-tetrachlorodi-μ-pivalatodirhenium(III) (cis-Re2((CH3)3CCOO)2Cl4.2DMSO, I) and cisplatin in the molar ratio of 4:1 as well as those loaded only with I were synthesized and characterized by scanning electron microscopy, transmission electron microscopy, dynamic light scattering and electronic absorption spectroscopy. The relative stability of liposomes loaded with I is reflected by a minimal change in the electronic absorption spectra over a period of 8 days whereas the stability of those loaded with both drugs is lower, which we ascribe to the formation of new Re-Pt species inside the liposomes. Furthermore, the investigations of the co-encapsulation effects on the anticancer activity of the Re-Pt system were undertaken. Importantly, the co-encapsulated liposomes exhibit synergistic or additive anticancer activities in vivo, e.g. introduction of these liposomes into tumor-bearing rats demonstrated their antianemic, nephro- and hepato-protecting effects. These liposomes, which are active in cancer treatment, protect the dirhenium compounds from hydrolysis and preserve the biological properties of the Re-Pt hybrid. This study reveals the importance of combined therapy in nanotechnology and medicine.
authors.affiliation: Department of Chemistry, Texas A&M University, College Station , Texas , USA.
authors.forename: Zhanyong
authors.initials: Z
authors.lastname: Li
authors.forename: Nataliia I
authors.initials: NI
authors.lastname: Shtemenko
authors.forename: Dina Y
authors.initials: DY
authors.lastname: Yegorova
authors.forename: Svetlana O
authors.initials: SO
authors.lastname: Babiy
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Brown
authors.forename: Tinglu
authors.initials: T
authors.lastname: Yang
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Shtemenko
authors.forename: Kim R
authors.initials: KR
authors.lastname: Dunbar
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D008081:Liposomes; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010316:Particle Size; D017208:Rats, Wistar; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D008081:Liposomes; D009942:Organometallic Compounds; C000601771:bis-dimethylsulfoxido-cis-tetrachlorodi-mu-pivalatodirhenium(III); D002945:Cisplatin
keywords: Cancer nanotherapy; cisplatin; dirhenium compounds; drug combination; lipid vesicles